GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
GENMAB A/S
Financials through fiscal 2025, year ended Dec 31, 2025
$38.50+1.50 (+4.05%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
102M of 64M shares
Institutional holders
290
50 new, 30 sold out
Net institutional buying
20M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 3,707,346 | 5.60% | 13G (passive) amendment | Mar 31, 2025 |
| Darwin Global Management, Ltd. | 3,668,310 | 5.90% | 13G (passive) | Sep 28, 2026 |
| Orbis Investment Management Ltd | 3,320,695 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GMAB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 13,133,131 | 20.40% | $360.77M | +5,165,295 | 6.76% |
| Orbis Allan Gray Ltd | 11,368,161 | 17.66% | $312.28M | −1,557,417 | 1.07% |
| Alliancebernstein L.P. | 8,644,877 | 13.43% | $231.94M | −912,272 | 0.08% |
| Deerfield Management Company, L.P. (Series C) | 6,865,000 | 10.66% | $188.58M | +4,403,000 | 1.97% |
| Deep Track Capital, LP | 5,650,000 | 8.78% | $155.21M | +1,986,750 | 2.26% |
| Arrowstreet Capital, Limited Partnership | 4,975,324 | 7.73% | $136.67M | – | 0.06% |
| BlackRock, Inc. | 4,671,252 | 7.26% | $128.32M | +134,687 | 0.00% |
| Sofinnova Investments, Inc. | 4,045,215 | 6.28% | $111.12M | +3,292,954 | 5.74% |
| Renaissance Technologies LLC | 3,517,850 | 5.46% | $96.64M | −896,700 | 0.13% |
| Two Sigma Investments, LP | 3,506,843 | 5.45% | $96.33M | +1,167,411 | 0.07% |
| Harding Loevner LP | 3,086,318 | 4.79% | $86.90M | −145,283 | 0.82% |
| First Trust Advisors LP | 2,756,522 | 4.28% | $75.72M | +295,180 | 0.04% |
| Citadel Advisors LLC | 2,475,991 | 3.85% | $68.02M | New | 0.01% |
| Qube Research & Technologies Ltd | 1,689,284 | 2.62% | $46.40M | +1,011,938 | 0.04% |
| Morgan Stanley | 1,630,161 | 2.53% | $44.78M | −554,540 | 0.00% |
| Federated Hermes, Inc. | 1,449,376 | 2.25% | $39.81M | +197,786 | 0.06% |
| Goldman Sachs Group Inc | 1,279,231 | 1.99% | $35.14M | +347,972 | 0.00% |
| Franklin Resources Inc | 1,202,923 | 1.87% | $33.04M | +9,778 | 0.01% |
| Pictet Asset Management Holding SA | 1,065,927 | 1.66% | $29.28M | −11,544 | 0.03% |
| UBS Group AG | 961,053 | 1.49% | $26.40M | +662,921 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 290 | 102M | 100.0% | 50 / 102 | 100 / 30 | 26M | 5M |
| Q1 2026 | 275 | 82M | 100.0% | 44 / 105 | 95 / 59 | 18M | 8M |
| Q4 2025 | 293 | 73M | 100.0% | 77 / 121 | 55 / 29 | 17M | 5M |
| Q3 2025 | 253 | 62M | 96.2% | 66 / 99 | 63 / 28 | 12M | 14M |
| Q2 2025 | 218 | 64M | 99.2% | 38 / 82 | 74 / 36 | 10M | 11M |
| Q1 2025 | 220 | 65M | 100.0% | 37 / 92 | 67 / 41 | 14M | 9M |
| Q4 2024 | 229 | 61M | 94.5% | 51 / 76 | 75 / 42 | 18M | 9M |
| Q3 2024 | 224 | 52M | 81.3% | 30 / 98 | 65 / 24 | 10M | 1M |
| Q2 2024 | 220 | 49M | 75.8% | 27 / 68 | 94 / 34 | 4M | 5M |
| Q1 2024 | 227 | 50M | 77.6% | 42 / 88 | 72 / 40 | 5M | 3M |
| Q4 2023 | 226 | 48M | 74.3% | 43 / 54 | 103 / 46 | 10M | 9M |
| Q3 2023 | 234 | 48M | 73.8% | 41 / 96 | 56 / 21 | 8M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GMAB | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Biotechnology ETF | 3,701,095 | 5.75% | $101.67M | 1.12% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 2,686,600 | 4.17% | $73.80M | 2.62% | Jun 30, 2026 |
| Ab Large Cap Growth Fund Inc | 1,692,412 | 2.63% | $46.49M | 0.20% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 520,700 | 0.81% | $15.03M | 0.31% | Jul 31, 2026 |
| Avantis International Equity ETF | 512,663 | 0.80% | $13.50M | 0.08% | May 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 350,000 | 0.54% | $10.10M | 0.35% | Jul 31, 2026 |
| Federated Hermes International Leaders Fund | 343,771 | 0.53% | $9.05M | 0.59% | May 31, 2026 |
| Tax-Managed U.S. Large Cap Fund | 342,344 | 0.53% | $9.88M | 0.08% | Jul 31, 2026 |
| Mercer Non-US Core Equity Fund | 179,676 | 0.28% | $4.94M | 0.10% | Jun 30, 2026 |
| SA AB Growth Portfolio | 161,398 | 0.25% | $4.66M | 0.26% | Jul 31, 2026 |
| Tema Oncology ETF | 158,861 | 0.25% | $4.18M | 2.37% | May 31, 2026 |
| LVIP AllianceBernstein Large Cap Growth Fund | 157,566 | 0.24% | $4.33M | 0.27% | Jun 30, 2026 |
| Timothy Plan International Fund | 137,000 | 0.21% | $3.76M | 1.59% | Jun 30, 2026 |
| AB Large Cap Growth Portfolio | 105,277 | 0.16% | $2.89M | 0.28% | Jun 30, 2026 |
| U.S. Strategic Equity Fund | 104,293 | 0.16% | $3.01M | 0.10% | Jul 31, 2026 |
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Judith V. Klimovsky Director | Jun 17, 2025 | 1,300 | $67.20K | Jun 17, 2025 | Stock Award |
| Judith V. Klimovsky Officer | Mar 1, 2024 | 1,200 | $330.00K | Mar 1, 2024 | Stock Award |